| 产品描述: | Arimoclomol citrate (BRX-220 citrate) is an orally active co-inducer of heat shock proteins (HSP). Arimoclomol citrate protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system. Arimoclomol citrate can be used for the study of Niemann–Pick disease type C. |
| 靶点: |
HSP |
| 体外研究: |
Arimoclomol (BRX-220; 20 mg/kg; orally administered for 5 d) has a protective effect against cholecystokinin-octapeptide (CCK)-induced acute pancreatitis[1]. |
| 参考文献: |
1. Rakonczay Z Jr, et al. Nontoxic heat shock protein coinducer BRX-220 protects against acute pancreatitis in rats. Free Radic Biol Med. 2002 Jun 15;32(12):1283-92. 2. Phukan J. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Jul;13(7):482-96. |
| 保存条件: |
-80°C 12个月; -20°C 6个月, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.977 ml |
9.883 ml |
19.767 ml |
| 5 mM |
0.395 ml |
1.977 ml |
3.953 ml |
| 10 mM |
0.198 ml |
0.988 ml |
1.977 ml |
| 50 mM |
0.04 ml |
0.198 ml |
0.395 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |